[Translation] A phase 1, randomized, double-blind study comparing the effects of oral omadacycline tosylate tablets and oral moxifloxacin hydrochloride tablets on the intestinal flora in healthy adult subjects

本研究的主要目的是评估口服甲苯磺酸奥马环素对肠道菌群耐药性的影响。

[Translation]

The primary objective of this study was to evaluate the effect of oral omadacycline tosylate on drug resistance in the intestinal flora.

Start Date23 Apr 2024

Sponsor / Collaborator

Zai Lab (Shanghai) Co., Ltd.

[+1]

NCT06462326 / CompletedPhase 1

A Phase 1, Randomized, Double-Blind Study to Compare the Effect of Omadacycline PO Versus Moxifloxacin PO on the Gut Microbiota in Healthy Adult Volunteers

This is a randomized (1:1), double-blind, double-dummy, phase I study to compare the effects of Omadacycline versus Moxifloxacin on gut microbiota and the resistomes in healthy adult volunteers.The study consists of 3 phases: Screening, double-blind treatment, and follow-up. Healthy volunteers aged 18-40 years, who meet entry criteria, are randomly assigned to a treatment group using an Interactive Voice Response System/Interactive Web Response System (IxRS) and receive the first dose of the study drug.

Start Date16 Apr 2024

Sponsor / Collaborator

Zai Lab (Hong Kong) Ltd.

CTR20232386 / RecruitingPhase 3

一项3b期、随机、双盲、多中心临床研究：比较奥马环素IV/PO与莫西沙星IV/PO治疗成人社区获得性细菌性肺炎（CABP）受试者的安全性与有效性

[Translation] A phase 3b, randomized, double-blind, multicenter clinical study to compare the safety and efficacy of omadacycline IV/PO versus moxifloxacin IV/PO in the treatment of adult subjects with community-acquired bacterial pneumonia (CABP)

主要目的：本研究的主要目的是显示在中国成人CABP患者中，奥马环素（iv/po）和莫西沙星（iv/po）的临床有效性相似。本研究设计为桥接研究，旨在在中国患者中证实奥马环素治疗成人社区获得性细菌性肺炎的疗效（CABP）与全球临床研究结果一致。次要目的：评估早期临床应答（ECR，研究药物首次给药后72-120小时）和治疗后评估（PTE）访视时的临床应答率（根据治疗结束[EOT]和PTE访视的研究者评估）；在安全性人群中评估奥马环素治疗中国成人CABP受试者的安全性；根据确认的基线致病病原体评估临床应答

[Translation]

Primary objective: The primary objective of this study is to show that the clinical efficacy of omadacycline (iv/po) and moxifloxacin (iv/po) is similar in Chinese adult CABP patients. This study is designed as a bridging study to confirm the efficacy of omadacycline in treating adult community-acquired bacterial pneumonia (CABP) in Chinese patients consistent with global clinical research results. Secondary objectives: To evaluate the early clinical response (ECR, 72-120 hours after the first dose of study drug) and the clinical response rate at the post-treatment evaluation (PTE) visit (based on the investigator assessment of the end of treatment [EOT] and PTE visits); to evaluate the safety of omadacycline in the treatment of Chinese adult CABP subjects in the safety population; to evaluate clinical response according to confirmed baseline pathogens

Start Date28 Nov 2023

Sponsor / Collaborator

Zhejiang Hisun Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Omadacycline Tosylate

100 Translational Medicine associated with Omadacycline Tosylate

100 Patents (Medical) associated with Omadacycline Tosylate

286

Literatures (Medical) associated with Omadacycline Tosylate

01 Dec 2024·Diagnostic Microbiology and Infectious Disease

Omadacycline for the treatment of severe Legionella pneumophila pneumonia complicated with multiple organ dysfunction: a case report

Article

Author: Fan, Lan ; Luo, Ping ; Wu, Cuifang ; Liu, Shao ; Liu, Chun ; Lv, Jinfeng

Omadacycline is a novel tetracycline antibiotic that has a strong in vitro antibacterial activity against atypical pathogen such as Legionella. It is approved for the treatment of adults with community-acquired bacterial pneumonia, including Legionella pneumonia. However, clinical data on the use of omadacycline in Legionella pneumonia is limited. In the present paper, we report a case of severe pneumonia induced by Legionella pneumophila (L.pneumophila) presenting with septic shock and multiple organ dysfunction including lung, liver and kidney. With omadacycline treaetment, inflammation indices of the patient markedly decreased, and the patient significantly improved with multiple organ dysfunction and was discharged from home. Due to its strong antibacterial activity against L.pneumophila, good safety profile and no dosage adjustment in patients with severe hepatic or renal impairment, omadacycline can be considered as an optimal treatment strategies for severe infections by such special pathogen. Whereas, more case reports are needed to support this conclusion.

04 Nov 2024·Journal of Antimicrobial Chemotherapy

Clinically important interactions of macrolides and tetracyclines with dietary interventions—a systematic review with meta-analyses

Review

Author: Wiesner, Agnieszka ; Zagrodzki, Paweł ; Paśko, Paweł ; Gawalska, Alicja

AbstractBackgroundEffective management of drug–food interactions is crucial for enhancing antibiotics’ efficacy/safety. Adhering to PRISMA guidelines, we conducted a systematic review to assess the impact of dietary interventions on the bioavailability of 15 macrolides and 10 tetracyclines.MethodsWe included studies examining the influence of food, beverages, antacids, and mineral supplements on the pharmacokinetic parameters of orally administered macrolides and tetracyclines. We searched Medline (via PubMed), Embase and Cochrane Library databases up to December 2022. Risk of bias was assessed using Cochrane and NIH tools. Quantitative analyses were conducted if two or more comparable food-effect studies were available; otherwise, a qualitative summary was provided.ResultsWe included 120 studies from 97 reports. Meta-analyses were conducted for 8 macrolides and 4 tetracyclines, with qualitative synthesis for 10 and 9, respectively. About 64% of the studies were open-label, crossover designs. Our assessment found that 37% of the studies had a high risk of bias, while only 6% had low risk. Food significantly affected 10 of 13 macrolides (77%) and 6 of 7 tetracyclines (86%). High positive effects on bioavailability were seen with extended-release azithromycin and clarithromycin, and erythromycin estolate. High negative impacts were observed with erythromycin propionate and stearate, azithromycin capsules, demeclocycline and omadacycline. Antacids and mineral supplements significantly decreased tetracyclines absorption. Milk and grapefruit juice showed variable impacts on absorption.DiscussionInteractions depend on antibiotics’ physicochemical characteristics, intervention type, drug formulation and potential patient factors. The quality of evidence was rated low due to outdated studies, methodological diversity and unequal data availability.

01 Nov 2024·The International Journal of Tuberculosis and Lung Disease

Omadacycline enhances the in vitro activity of clofazimine against Mycobacterium abscessus

Article

Author: Ammerman, N.C. ; de Steenwinkel, J.E.M. ; Meliefste, H.M. ; Mudde, S.E. ; Bax, H.I.

News (Medical) associated with Omadacycline Tosylate

14 Nov 2024

·www.globenewswire.com

Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing Capabilities

-- Onshoring of NUZYRA is a Key Deliverable in Company’s Partnership with U.S. Biomedical Advanced Research and Development Authority (BARDA) to Enhance National SecurityBOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, announces that its U.S. supply and manufacturing capabilities for its novel antibiotic NUZYRA® (omadacycline) are now complete. NUZYRA is the company's broad-spectrum, novel antibiotic available in both intravenous and oral formulations approved by the U.S. Food and Drug Administration (FDA) for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). “Establishing a U.S. manufacturing and supply chain is the culmination of one of the most important elements of our public-private partnership with BARDA, an agreement intended to strengthen our national security,” said Evan Loh, M.D., Paratek chief executive officer. “This onshoring milestone is significant because it ensures that NUZYRA has a secure domestic supply chain that reduces dependency on foreign production and decreases the national security risk for the manufacturing and supply of antibiotics.” Major onshoring milestones that established the U.S. capabilities included the successful technology transfer by Paratek and its manufacturing partners and related FDA approval/implementation for 1) U.S. manufacturing of NUZYRA tablets in 2022; 2) U.S. manufacturing of the active pharmaceutical ingredient (API) as of August 2024; and 3) U.S. manufacturing of NUZYRA’s IV formulation (vials) in October 2024. “Paratek continues to deliver on the milestones of this important agreement with BARDA, in many cases exceeding agreed-upon timelines, thanks to ongoing, highly productive collaboration and communication between BARDA and Paratek,” said Randy Brenner, Paratek's chief development and regulatory officer. “We are grateful to BARDA for their partnership and look forward to completing our studies to support our sNDA filing for NUZYRA for treatment and prophylaxis of pulmonary anthrax in the near term.” This project has been supported in whole or in part with federal funds from the Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50120C00001. About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings. The company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek has a collaboration agreement with Zai Lab Limited for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights. Zai Lab received approval for both IV and oral NUZYRA as a Category 1 innovative drug by the National Medical Products Administration of China for the treatment of CABP and ABSSSI in December 2021 and in Macao for the treatment of CABP and ABSSSI in May 2023. In December 2019, BARDA awarded Paratek a contract (75A50120C00001) that is now valued at up to approximately $304 million. In addition to supporting the development of NUZYRA for both the treatment and prophylaxis of pulmonary anthrax, this contract supports the U.S. onshoring of NUZYRA and manufacturing security requirements; FDA post-marketing requirements associated with the initial NUZYRA approval; and the procurement of up to 10,000 treatment courses of NUZYRA for the treatment of anthrax. Paratek is conducting a Phase 2b study with NUZYRA in a rare disease, non-tuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex. For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter. About NUZYRA®NUZYRA® (omadacycline) is an antibiotic with both once-daily oral and intravenous (IV) formulations indicated for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible microorganisms. A next generation tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypical and other drug-resistant strains. IMPORTANT SAFETY INFORMATIONCONTRAINDICATIONSNUZYRA is contraindicated in patients with known hypersensitivity to omadacycline or tetracycline-class antibacterial drugs, or to any of the excipients. WARNINGS AND PRECAUTIONSMortality imbalance was observed in the CABP clinical trial with eight deaths (2%) occurring in patients treated with NUZYRA compared to four deaths (1%) in patients treated with moxifloxacin. The cause of the mortality imbalance has not been established. All deaths, in both treatment arms, occurred in patients > 65 years of age; most patients had multiple comorbidities. The causes of death varied and included worsening and/or complications of infection and underlying conditions. Closely monitor clinical response to therapy in CABP patients, particularly in those at higher risk for mortality. The use of NUZYRA during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.The use of NUZYRA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth. Hypersensitivity reactions have been reported with NUZYRA. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with other tetracycline-class antibacterial drugs. NUZYRA is structurally similar to other tetracycline-class antibacterial drugs and is contraindicated in patients with known hypersensitivity to tetracycline-class antibacterial drugs. Discontinue NUZYRA if an allergic reaction occurs. Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs. NUZYRA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions, including photosensitivity, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests), have been reported for other tetracycline-class antibacterial drugs, and may occur with NUZYRA. Discontinue NUZYRA if any of these adverse reactions are suspected. Prescribing NUZYRA in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. ADVERSE REACTIONSThe most common adverse reactions (incidence ≥2%) are nausea, vomiting, infusion site reactions, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyl transferase increased, hypertension, headache, diarrhea, insomnia, and constipation. DRUG INTERACTIONSPatients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage while taking NUZYRA. Absorption of tetracyclines, including NUZYRA is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron containing preparations. USE IN SPECIFIC POPULATIONSLactation: Breastfeeding is not recommended during treatment with NUZYRA. See full prescribing information here. MEDIA CONTACT: Christine Fanelle Scient PR Christine@ScientPR.com215-595-5211

Drug ApprovalLicense out/inPhase 2Clinical Result

08 Nov 2024

·www.globenewswire.com

Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary Disease

First randomized placebo-controlled trial in NTM abscessusSymptom-based endpoints showed favorable improvement in frequency and severity of the most common symptomsMicrobiologic endpoints showed higher conversion to negative sputum culture, without emergence of resistance to omadacyclineIn this 12-week study, omadacycline appeared to be safe and well-tolerated with no new or unexpected safety signals BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for serious diseases, today announced top-line results from its Phase 2b study of oral omadacycline in adult patients with Nontuberculous Mycobacterial (NTM) pulmonary disease caused by Mycobacterium abscessus complex (MABc). “The results from this first-ever placebo-controlled trial in MABc patients are exciting and support the idea that omadacycline has clinical utility in this very challenging disease setting. Omadacycline treatment demonstrated positive results across multiple clinical and microbiological endpoints in the study,” said Kevin Winthrop, M.D., M.P.H., Center for Infectious Disease Studies, at Oregon Health and Science University and Principal Investigator in the study, “The results suggest its potential to become an important addition to the very limited treatment options currently available for patients with Mycobacterium abscessus, providing hope for improved patient outcomes. This is something that clinicians and patients in the NTM community should be very encouraged by.” The Phase 2b double-blind, placebo-controlled, randomized study evaluated the safety, efficacy, and tolerability of omadacycline in patients with Mycobacterium abscessus pulmonary disease. Sixty-six patients were randomized 1.5:1 to treatment with omadacycline (n= 41) or placebo (n=25) for 84 days, followed by a 30-day safety follow-up period. While the study was not designed to formally test for statistical differences between treatment arms, a trend favoring omadacycline was consistently observed across top line primary and secondary endpoints. The primary efficacy endpoint was the response on the NTM Symptom Assessment Scale at Day 84 and was evaluated 2 different ways. The first (Evaluation 1) defined a positive response as an improvement in at least 50% of the NTM symptoms present at baseline. The second (Evaluation 2) was a more stringent approach, requiring improvement in at least 50% of the NTM symptoms present at baseline AND no worsening of any baseline symptom. Omadacycline-treated subjects demonstrated a favorable trend towards higher response rates compared with placebo-treated subjects for both Evaluation 1 (34.1% vs 20%; p = 0.218) and Evaluation 2 (34.1% vs 12%; p = 0.046). The Quality of Life-Bronchiectasis (QOL-B), a patient-reported outcomes measure, favored omadacycline across all domains, particularly in vitality, physical functioning, social functioning, and respiratory symptoms. In addition, both patient and clinician assessments of clinical status improved over time in the omadacycline-treated group, while the placebo group showed worsening or no change. On microbiological endpoints, omadacycline-treated patients had a higher rate of negative sputum cultures for MABc (56.4% vs 29.2%, p=0.035) and a greater reduction in semi-quantitative sputum culture scores (76.5% vs 45.8%, p=0.017) at day 84 compared to placebo. Oral omadacycline administered for up to 12 weeks was generally safe and well-tolerated. The safety profile was consistent with the established profile for NUZYRA® (omadacycline), and no new safety signals were observed over this treatment period. The most common treatment-emergent adverse events were gastrointestinal symptoms. No deaths occurred in the study. Two subjects in the placebo-group experienced serious adverse events. Treatment discontinuation due to adverse events occurred in four (9.8%) omadacycline-treated patients. “These findings add to a growing dataset that supports the potential for symptomatic and microbiological improvement with omadacycline for those patients struggling with MABc pulmonary disease.” said Evan Loh, M.D., Chief Executive Officer of Paratek Pharmaceuticals. “This community needs better treatment options. I want to thank the patients, caregivers, and investigators who participated and made this encouraging outcome possible.” Analysis of all study data is ongoing and the complete data from this study will be presented in the future and published in a peer-reviewed journal. About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative treatments for life-threatening diseases and other public health threats. Paratek’s lead product, NUZYRA® (omadacycline), is a novel antibiotic that addresses serious community-acquired infections. The company is dedicated to advancing solutions that address critical unmet medical needs, including those for rare and difficult-to-treat diseases such as NTM. For more information, visit www.paratekpharma.com or follow us on LinkedIn and Twitter. For more information, visit www.ParatekPharma.com or follow us on LinkedIn and X.com. About NUZYRA® NUZYRA® (omadacycline) is an antibiotic with both once-daily oral and intravenous (IV) formulations indicated for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible microorganisms. A next generation tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypical and other drug-resistant strains. IMPORTANT SAFETY INFORMATIONCONTRAINDICATIONSNUZYRA is contraindicated in patients with known hypersensitivity to omadacycline or tetracycline-class antibacterial drugs, or to any of the excipients. WARNINGS AND PRECAUTIONSMortality imbalance was observed in the CABP clinical trial with eight deaths (2%) occurring in patients treated with NUZYRA compared to four deaths (1%) in patients treated with moxifloxacin. The cause of the mortality imbalance has not been established. All deaths, in both treatment arms, occurred in patients > 65 years of age; most patients had multiple comorbidities. The causes of death varied and included worsening and/or complications of infection and underlying conditions. Closely monitor clinical response to therapy in CABP patients, particularly in those at higher risk for mortality. The use of NUZYRA during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia. The use of NUZYRA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth. Hypersensitivity reactions have been reported with NUZYRA. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with other tetracycline-class antibacterial drugs. NUZYRA is structurally similar to other tetracycline-class antibacterial drugs and is contraindicated in patients with known hypersensitivity to tetracycline-class antibacterial drugs. Discontinue NUZYRA if an allergic reaction occurs. Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs. NUZYRA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions, including photosensitivity, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests), have been reported for other tetracycline-class antibacterial drugs, and may occur with NUZYRA. Discontinue NUZYRA if any of these adverse reactions are suspected. Prescribing NUZYRA in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. ADVERSE REACTIONSThe most common adverse reactions (incidence ≥2%) are nausea, vomiting, infusion site reactions, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyl transferase increased, hypertension, headache, diarrhea, insomnia, and constipation. DRUG INTERACTIONSPatients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage while taking NUZYRA. Absorption of tetracyclines, including NUZYRA is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron containing preparations. USE IN SPECIFIC POPULATIONSLactation: Breastfeeding is not recommended during treatment with NUZYRA. See full prescribing information here. MEDIA CONTACT: Sarah Misheksmishek@scientpr.com

Clinical ResultPhase 2Drug Approval

14 Oct 2024

·www.globenewswire.com

Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024

-- Highlights include data from clinical, non-clinical and microbiology programs, real-world patient use and a five-year microbiologic surveillance study of NUZYRA BOSTON, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, announces that data from several new studies of NUZYRA® (omadacycline) will be presented at IDWeek 2024, Oct. 16-19 at the Los Angeles Convention Center in Los Angeles, CA. “We continue to invest in science as part of our continued commitment to furthering the medical community’s understanding of NUZYRA’s potential utility across a broad range of serious, community-acquired infections, including pulmonary and skin infections,” said Randy Brenner, chief development and regulatory officer of Paratek. “Notably, researchers will share the interim safety results of an open-label, non-inferiority trial of NUZYRA in the treatment of bone and joint infections as well as data from a real-world study assessing both clinical and microbiological outcomes of treatment with NUZYRA for pulmonary Mycobacterium abscessus complex, a rare pulmonary disease that Paratek is also evaluating in a Phase 2 study.” Oral Presentations Abstract title: Improving Traditional Registrational Trial Endpoints: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Acute Bacterial Skin and Skin-Structure InfectionsSession: Breaking Ground: ID Clinical TrialsPresenter: Jessica Renee Howard-Anderson, M.D., M.Sc. (Independent research)Session Date, Time: Thursday, Oct. 17; 10:30 a.m. - 11:45 a.m. (PT) Session Location: 404 ABSubmission ID: 1828901 Abstract title: Evaluation of Fecal Pharmacokinetics and Metagenomic Changes Following the Administration of Intravenous Omadacycline to Healthy SubjectsSession: Hot Topics in Microbiome SciencePresenter: Kevin Garey, Pharm.D. (Investigator-initiated research)Session Date, Time: Friday, Oct. 18; 3:15 p.m. - 4:30 p.m. (PT)Session Location: 411Submission ID: 1828708 Abstract title: Clinical and Microbiological Outcomes of Omadacycline for Pulmonary Mycobacterium Abscessus Complex Session: TB and Nontuberculous Mycobacteria UpdatesPresenter: Mohammed Al Musawa, Pharm.D., BCIDP (Investigator-initiated research)Session Date, Time: Saturday, Oct. 19; 3:15 p.m. - 4:30 p.m. (PT) Session Location: 403 ASubmission ID: 1828690 Poster Sessions Poster title: Safety of Omadacycline Versus Standard-of-Care Oral Antibiotic Treatment for Bone and Joint Infections: Interim Results from an Open-Label, Non-Inferiority, Randomized Controlled Trial Poster Session Title: Bone and JointPresenter: Amy Y. Kang, Pharm.D., BCIDP (Investigator-initiated research)Date, Time: Thursday, Oct. 17; 12:15 p.m. - 1:30 p.m. (PT) Location: Hall J & KSubmission ID: 1828407 Rapid Fire and Poster title: Activity of Omadacycline Against 35,000 Bacterial Clinical Isolates and Resistant Organism Subsets from Patients in the United States (2019–2023)Poster session: HAIs: SurveillancePresenter: Michael Huband, B.S. (Paratek research)Date, Time: Thursday, Oct. 17, 2024; 12:15 p.m. - 1:30 p.m. (PT)Location: Hall J & KSubmission ID: 1817385 Poster title: In Vitro Activity of Omadacycline and Comparator Agents against a Collection of Neisseria Gonorrhoeae Urine Isolates Collected from the United States During 2018-2020 Poster session: Treatment of Antimicrobial Resistant InfectionsPresenter: S.J. Ryan Arends, Ph.D. (Paratek research)Date, Time: Friday, Oct. 18; 12:15 p.m. - 1:30 p.m. (PT)Location: Hall J & KSubmission ID: 1829425 Poster title: Current Prescribing Practices and Guideline Concordance for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) across Outpatient and Urgent Care Visits Poster session: Antibiotic Stewardship: Non-Inpatient SettingsPresenter: Tomefa Asempa, Pharm.D. (Investigator-initiated research)Date, Time: Saturday, Oct. 19, 12:15 p.m. - 1:30 p.m. (PT)Location: Hall J & KSubmission ID: 1827423 About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings. The company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek has a collaboration agreement with Zai Lab Limited for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights. Zai Lab received approval for both IV and oral NUZYRA as a Category 1 innovative drug by the National Medical Products Administration of China for the treatment of CABP and ABSSSI in December 2021 and in Macao for the treatment of CABP and ABSSSI in May 2023. Paratek is also conducting a Phase 2b study with NUZYRA in a rare disease, non-tuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex. In December 2019, BARDA awarded Paratek a contract (75A50120C00001) that is now valued at up to approximately $304 million. In addition to supporting the development of NUZYRA for both the treatment and prophylaxis of pulmonary anthrax, this contract supports the U.S. onshoring of NUZYRA and manufacturing security requirements; FDA post-marketing requirements associated with the initial NUZYRA approval; and the procurement of up to 10,000 treatment courses of NUZYRA for the treatment of anthrax. For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter. About NUZYRA®NUZYRA® (omadacycline) is an antibiotic with both once-daily oral and intravenous (IV) formulations indicated for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible microorganisms. A next generation tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals and other drug-resistant strains. IMPORTANT SAFETY INFORMATIONCONTRAINDICATIONSNUZYRA is contraindicated in patients with known hypersensitivity to omadacycline or tetracycline-class antibacterial drugs, or to any of the excipients. WARNINGS AND PRECAUTIONSMortality imbalance was observed in the CABP clinical trial with eight deaths (2%) occurring in patients treated with NUZYRA compared to four deaths (1%) in patients treated with moxifloxacin. The cause of the mortality imbalance has not been established. All deaths, in both treatment arms, occurred in patients > 65 years of age; most patients had multiple comorbidities. The causes of death varied and included worsening and/or complications of infection and underlying conditions. Closely monitor clinical response to therapy in CABP patients, particularly in those at higher risk for mortality. The use of NUZYRA during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.The use of NUZYRA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth. Hypersensitivity reactions have been reported with NUZYRA. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with other tetracycline-class antibacterial drugs. NUZYRA is structurally similar to other tetracycline-class antibacterial drugs and is contraindicated in patients with known hypersensitivity to tetracycline-class antibacterial drugs. Discontinue NUZYRA if an allergic reaction occurs. Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs. NUZYRA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions, including photosensitivity, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests), have been reported for other tetracycline-class antibacterial drugs, and may occur with NUZYRA. Discontinue NUZYRA if any of these adverse reactions are suspected. Prescribing NUZYRA in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. ADVERSE REACTIONSThe most common adverse reactions (incidence ≥2%) are nausea, vomiting, infusion site reactions, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyl transferase increased, hypertension, headache, diarrhea, insomnia, and constipation. DRUG INTERACTIONSPatients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage while taking NUZYRA. Absorption of tetracyclines, including NUZYRA is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron containing preparations. USE IN SPECIFIC POPULATIONSLactation: Breastfeeding is not recommended during treatment with NUZYRA. See full prescribing information here. MEDIA CONTACT: Christine Fanelle Scient PR Christine@ScientPR.com215-595-5211

Phase 2License out/inDrug ApprovalClinical Result

100 Deals associated with Omadacycline Tosylate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Omadacycline Tosylate	J01AA15	DB12455

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Community-acquired bacterial pneumonia	US	Paratek Pharmaceuticals, Inc.	02 Oct 2018
Skin and skin structure infections	US	Paratek Pharmaceuticals, Inc.	02 Oct 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Skin and skin structure infections	Phase 2	TR	Paratek Pharmaceuticals, Inc.	01 Jun 2015
Skin and skin structure infections	Phase 2	BG	Paratek Pharmaceuticals, Inc.	01 Jun 2015
Skin and skin structure infections	Preclinical	PL	Paratek Pharmaceuticals, Inc.	01 Jun 2015
Skin and skin structure infections	Preclinical	LV	Paratek Pharmaceuticals, Inc.	01 Jun 2015
Skin structures and soft tissue infections	Preclinical	-	Paratek Pharmaceuticals, Inc.	01 Jul 2009
Skin structures and soft tissue infections	Preclinical	-	Paratek Pharmaceuticals, Inc.	01 Jul 2009
Complicated skin and skin structure infection	Preclinical	US	Paratek Pharmaceuticals, Inc.	04 Apr 2009
Complicated skin and skin structure infection	Preclinical	US	Novartis Pharmaceuticals Corp.	04 Apr 2009
Skin Diseases, Infectious	Preclinical	US	Paratek Pharmaceuticals, Inc.	04 Apr 2009
Skin Diseases, Infectious	Preclinical	US	Novartis Pharmaceuticals Corp.	04 Apr 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02378480 \| NCT02877927 (OASIS-1, Pubmed \| Infect Dis Ther) Manual	Phase 3	Skin Diseases, Bacterial	-	Intravenous Omadacycline/linezolid	(qthflouxqq) = wztodzyjyf juzgtzfrnb (bwwqhyqyeu ) View more	Positive	26 Oct 2024
				Oral Omadacycline/linezolid	(qthflouxqq) = qqiidahhio juzgtzfrnb (bwwqhyqyeu ) View more
GlobeNewswire Manual	Approved	Community-acquired bacterial pneumonia	670	NUZYRA® (omadacycline)	(rszzdcjfxt) = rznizvqypp hcupsdngql (yfirngifas ) Met View more	Positive	18 Jul 2024
				Moxifloxacin	(rszzdcjfxt) = yxauquwyhd hcupsdngql (yfirngifas ) Met View more
75A50120C00001 (GlobeNewswire) Manual	Not Applicable	Inhalation Anthrax	-	NUZYRA	(nrxsrlbqla) = nzdjqxkcoe gjvfhiluob (ditvvptbas ) View more	Positive	05 Mar 2024
NCT04922554 (Phase 2, Pubmed \| JAC Antimicrob Resist)	Phase 2	-	-	Omadacycline	nxmhxhktzz(qbzrtpouea) = fsdiauslml goysbypywk (xvlbibcpbp )	Positive	01 Oct 2023
NCT02531438 (OPTIC, Pubmed)	Phase 3	Community-acquired bacterial pneumonia	774	Omadacycline	(tsxxbwohnz) = lzxtgjzsgc skqjduoldg (ntefthcpkq )	Positive	01 Jan 2023
				Moxifloxacin	(tsxxbwohnz) = pmflukhcxi skqjduoldg (ntefthcpkq )
NCT02531438 \| NCT02378480 \| NCT02877927 (Pubmed)	Phase 3	Pneumonia \| Soft Tissue Infections	-	Omadacycline	(formlkqjii) = bwnhvbwpoi ictdrmdurr (nerfjdxqwr ) View more	Positive	01 Jun 2022
				Linezolid	(formlkqjii) = tgzzzkxcab ictdrmdurr (nerfjdxqwr ) View more
ATS2022	Not Applicable	Mycobacterium Abscessus Infection	26	Omadacycline	hzsinmtmey(hjjfxovexw) = weight loss, intractable nausea, eosinophilia, and abnormal hepatic function testing romohkiyhu (ukjbanrpyt ) View more	Positive	15 May 2022
NCT04160260 (CTgov)	Phase 1	Community-acquired bacterial pneumonia	18	Omadacycline	ztwmswvudf(mygmxsmsom) = oeqovtkelo gxwbokmdmo (mdkuzubwgd, etmkgnwqbq - cbciitrvyt) View more	-	03 Nov 2021
NCT03757234 (CTgov)	Phase 2	Acute pyelonephritis	201	Omadacycline (Omadacycline 200 iv/200 iv)	ytpytwfwno(mmfdbwbxko) = utryruiiog dbfynmxuqr (myeymiqqwb, absgaevpep - nsozsqgydi) View more	-	07 Jul 2020
				Omadacycline (Omadacycline 200 iv/100 iv)	ytpytwfwno(mmfdbwbxko) = apjhcrrizk dbfynmxuqr (myeymiqqwb, cmhncjnylc - ptveopvlux) View more
NCT03425396 (CTgov)	Phase 2	Urinary Tract Infections \| Cystitis	225	Omadacycline tablets (Omadacycline 300/300 Once Every 24 Hours)	jftuiddmvz(oxgonvuaki) = jcnvimfzgw uqnonstren (vuyeffamum, gyhtxgbbgw - qtiwonjaly) View more	-	04 Jun 2020
				Omadacycline tablets (Omadacycline 450/300 Once Every 24 Hours)	jftuiddmvz(oxgonvuaki) = xewvplpsdb uqnonstren (vuyeffamum, licjolehho - ronlijfqwm) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis